Articles On Phylogica (ASX:PYC)

ASX burns through 118 points or 1.36% Energy only sector in green after crude oil gains Broad retreat after three straight weeks of losses   ASX falls three weeks in a row It was a day of bloodletting on the ASX 200 today, plummeting 118...

PYC Therapeutics (ASX:PYC) has reported its investigational drug candidate, VP-001, has shown success in patients with Retinitis Pigmentosa type 11 (RP11) in Phase 1/2 clinical trials where improvements were reported by patients for up to 1...

The latest quarterlies show that key drug and diagnostics developers are well funded for the task Cann Group enters company-saving debt and equity restructuring deal A rebirth for Monash IVF?      Today’s crop of quarterly reports shows t...

The S&P/ASX 200 Index (ASX: XJO) is having a good session on Thursday. In afternoon trade, the benchmark index is up 0.4% to 8,983.9 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's w...

The S&P/ASX 200 Index (ASX: XJO) is on form again on Monday. At the time of writing, the benchmark index is up 0.3% to 8,797.7 points. Four ASX shares rising more than most today are listed below. Here's why they are climbing: Newmont...

ASX pares back early gains to lift 0.32pc Healthcare, tech, utilities drive gains Resources sector drags as gold prices slip from highs ASX gets clean bill of health The ASX was looking a little healthier today, adding 0.32% or 28.3 poi...

 Oncosil will accelerate the rollout of its targeted radiation device after promising trial results Imricor completes ‘human factor’ ablation catheter study PYC’s CEO departure is “disappointing”, opines broker   The developer of a targe...

It looks set to be a day to forget for shareholders of one ASX All Ords stock. That's because in early trade, its shares are down a whopping 29% to 86.5 cents. Which ASX All Ords stock is crashing? The stock taking a major hit today is PYC...

Australian shares are heading towards a -0.43% dip at open on Wednesday, with global markets edgy ahead of the Federal Reserve’s big rate cut call – even considering the trim is “100% happening” according to analysts. Listen to the HotCo...

Cervical cancer detection play Truscreen says its year is off to a good start PYC Therapeutics enters “transformational period” … as does Imagion Biosystems   Trans-Tasman cervical screening outfit Truscreen Group (ASX:TRU) has promised a...

If you have a high tolerance for risk, then it could be worth considering the speculative ASX stock in this article. That's because Bell Potter believes that investors could almost double their money in 12 months if everything goes to plan....

Biotechs can be a risky investment, but where the risks are high, so potentially are the gains. Wilsons Advisory forecasts more than 100% upside for PYC Therapeutics Ltd (ASX: PYC). PYC, which is valued at about $720m, is developing a...

Highlights ASX eases amid US Federal Reserve developments Gold stocks gain traction as gold prices rise Select large-cap companies show strong momentum The Australian share market traded with a softer tone during midday Friday, wi...

ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses   Profit takers stay their hands When markets hit new closing highs, it...

Highlights ASX 200 index trades close to record high Gains led by materials and coal stocks Peter Warren Automotive and Avita Medical see strong rallies The Australian share market advanced strongly on Wednesday, with...

 Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire     Nanosonics (ASX:NAN) has launched updated iteratio...

Highlights GYG, MEK, and PYC listed on ASX 200 show strong earnings momentum and executive backing GYG operates in quick service food with strong sector performance amid retail shifts MEK and PYC represent high-growth potent...

The ASX 200 closed up 0.1% at 8,361 points. IT was the best performing sector, followed by Materials, up 0.45%, and Discretionary, up 0.3%. Utilities was by far the worst performing sector, down 2.4%, followed by Telecommunication, do...

Highlights Develop Global, Guzman y Gomez, and PYC Therapeutics feature among notable ASX growth stocks with high internal control. These companies operate in mining, food retail, and biotechnology sectors with diverse revenue so...

ASX heath sector up 1.9%, trailing ASX 200’s 2% gain in short week revival   Sleep-related respiratory disorders company ResMed reports “stronger than expected” Q3 FY25 results Imricor makes key regulatory strides in Q1 CY25, including sub...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

Highlights: Australian market experiences a modest rise, with the technology sector maintaining steady expansion. Companies such as PYC Therapeutics, Qoria, and WiseTech Global demonstrate strong revenue performance. Continu...

Highlights: Several ASX-listed companies have demonstrated high earnings expansion alongside substantial ownership from internal stakeholders. Businesses spanning sectors such as minerals, biotechnology, and consumer services exh...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

ASX small-cap shares are slightly outperforming in 2025, with the S&P/ASX Small Ordinaries Index (ASX: XSO) up 3.88% while the S&P/ASX 200 Index (ASX: XJO) is up 3.71% in the year-to-date. Many analysts have suggested this shoul...

Highlights ASX200 faces a 0.36% decline following new US tariffs on Australian aluminum and steel. Utilities and Health Care sectors show resilience, while IT, Technology, and Financials experience declines. Notable shifts in individu...

The ASX200 has been down 0.36% at 8,480 points through trade today. The local bourse has reacted negatively to the news the Trump administration is set to impose a 25% tariff on Aussie aluminium and steel. Utilities has been the best-...

  Ansell is expanding its manufacturing to be less reliant on China Mayne Pharma pre-announces a strong first-half earnings recovery Alterity Therapeutics raises $40 million on the back of encouraging trial   The maker of personal protect...

The ASX200 has hit yet another all-time high of 8,566 points in morning trade. The record was driven by a strong lead from Wall Street as well as buoyant mining and real estate stocks. Real Estate was the best performing sector, up 1....

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness. (Most gains, however, were quickly sold...

The ASX200 has been up 0.23% at 8,330 points. Donald Trump will be sworn in as the 47th President of the United States tomorrow Australian time, and investors are hyper alert to any potential surprises from the new President. Utilitie...

The S&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher on Monday. In afternoon trade, the benchmark index is up 0.4% to 8,345.1 points. Four ASX shares that have failed to follow the market higher today are listed below. H...

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

PYC Therapeutics (ASX:PYC) has nominated a fourth clinical drug candidate, PYC-002, targeting Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental disorder with no current treatment options. The Perth-based biotechnology company is pro...

ASX healthcare shares were in the red yesterday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.21% while the broader S&P/ASX All Ordinaries Index (ASX: XAO) was up 0.18%. Here are two ASX healthcare small-cap share...

S&P/ASX All Ords (ASX: XAO) shares soared 3.29% in November amid an early start to the traditional 'Santa Rally'. AMP Ltd (ASX: AMP) Head of Investment Strategy and Economics, Dr Shane Oliver, said markets were now in a "seasonally...

PYC Therapeutics Ltd (ASX:PYC) – a clinical biotech company which is progressing the first drug candidate to address childhood blinding eye disease Retinitis Pigmentosa type 11 – will be presenting data from its Phase 1/2 trial at a scienti...

The ASX200 closed down 0.4% at 8,131 points. The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus expectations. RBA Governor Michelle Bullock says the bank wants to be more convinced inflation is going t...

PYC Therapeutics (ASX:PYC) has has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11, in a second patient cohort. Dosages will be lifted to 75 micrograms (mcg). The second cohort comprises pat...

Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of Autosomal Dominant Optic Atrophy (ADAO). The condition is one which causes blindness and is commonly believed to...

PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for genetic diseases. The company is in the midst of clinical trials for its leading drug candidates targeting rare eye co...

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

ASX closes higher led by strong mining sector Wisetech and Mineral Resources suffer heavy losses amid scandals Gold prices soar past $US$2,700 on geopolitical tensions   The ASX rose on Monday after a solid run on Wall Street and some st...

Paradigm Biopharmaceuticals says it is ready to apply to the US regulator to start its delayed phase III trial for knee osteoarthritis AFT Pharmaceuticals has entered a deal with two European partners to develop a secret novel drug PYC The...

ASX set to rise on Monday after strong Wall Street gains Netflix shares up 11pc on strong profits TSMC crucial for chip production, and investors should watch this stock   The ASX is set to rally when the market resumes on Monday after a...

The ASX200 closed up nearly 0.95% at 8,203 points, amid China’s stimulus news and as iron ore rose to US$98.75 per tonne. The big miners all tracked the rise and chalked up gains. Crude oil continues its recent decline and is now trading...

It's been a big day for several ASX All Ords shares, with three companies in particular seeing strong gains. Novonix Ltd (ASX: NVX), PYC Therapeutics Ltd (ASX: PYC), and Strike Energy Ltd (ASX: STX) have all surged by more than 12%....

Health Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   PYC Therapeutics notes a growing valuation chasm between the data-rich, p...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

PYC Therapeutics Ltd (ASX:PYC) has announced that the US Food and Drug Administration (FDA) has granted ‘Rare Pediatric Disease (RPD)’ designation to its development program for a drug aimed at treating patients with blinding eye disease Au...